Versicor brought to the table a host of interesting programs early in the research pipeline and an antifungal drug, anidulafungin, which is now being evaluated by the FDA to treat invasive fungal infections that can damage the internal organs of patients with already compromised immune systems.

FORBES: Building An Antibiotic Powerhouse